{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:27:26Z","timestamp":1794328046763,"version":"4.9.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate the spectrum and the antimicrobial susceptibility of microorganisms causing bloodstream infections (BSIs) in a cohort of patients of a pediatric cancer unit. In addition, we evaluated the effectiveness of preventive antimicrobial lock therapy with taurolidine-citrate solution in reducing BSI rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We prospectively assessed demographic, clinical and microbiological data of BSIs during a 5-year period from January 2019 to December 2023. Preventive lock treatment with instillation of taurolidine-citrate solution into the central venous catheter (CVC) was performed from January 2019 to April 2022, interrupted from May to December 2022 and, after a suspected increase in BSI episodes, reintroduced from January 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In 45 patients, a total of 57 BSI episodes were recorded and 60 microorganisms were cultured. The most frequently isolated bacteria belonged to\n                      <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic>\n                      spp. (n = 20, 33.3%) and\n                      <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                      (n = 17, 28.3%). Regarding the antimicrobial susceptibility, all Gram-positive bacteria were susceptible to vancomycin. Among the Gram-negative bacteria, only 4 isolates (17.4%) showed a resistance against piperacillin\/tazobactam and only 1 isolate a resistance against meropenem (4.3%). Incidence of BSIs was highest from May to December 2022 (19.6 per 100 patient months; 95% confidence intervals: 11.0\u201332.4 per 100 patient months) when CVCs were locked with saline instead of taurolidine-citrate solution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      In this study,\n                      <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic>\n                      spp. and\n                      <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                      were the most frequently isolated microorganisms. The lock of CVCs with taurolidine apparently contributed to the prevention of BSIs in the above-mentioned patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005342","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:02:56Z","timestamp":1785211376000},"page":"e492-e496","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Surveillance of Bloodstream Infections in a German Pediatric Cancer Unit During a 5-Year Period: Microbial Spectrum, Antimicrobial Susceptibility and Effectiveness of Preventive Taurolidine Lock"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9342-4388","authenticated-orcid":false,"given":"Giuseppe","family":"Valenza","sequence":"first","affiliation":[{"name":"Mikrobiologisches Institut\u2013Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Chada","sequence":"additional","affiliation":[{"name":"Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3808-9605","authenticated-orcid":false,"given":"Sven","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, N\u00fcrnberg, Germany"},{"name":"Research group Aetiology and Inequalities in Childhood Cancer, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Esse","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut\u2013Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Held","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut\u2013Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bogdan","sequence":"additional","affiliation":[{"name":"Mikrobiologisches Institut\u2013Klinische Mikrobiologie, Immunologie und Hygiene, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"FAU Profile Center Immunomedicine, Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-1676","authenticated-orcid":false,"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[{"name":"Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t (FAU) Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"R1-20261110","first-page":"Doc11","article-title":"Surveillance of bloodstream infections in pediatric cancer centers: what have we learned and how do we move on?","volume":"11","author":"Simon","year":"2016","journal-title":"GMS Hyg Infect Control"},{"key":"R2-20261110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00431-015-2525-5","article-title":"Bloodstream infection in paediatric cancer centres - leukaemia and relapsed malignancies are independent risk factors.","volume":"174","author":"Ammann","year":"2015","journal-title":"Eur J Pediatr"},{"key":"R3-20261110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-8-102","article-title":"Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.","volume":"8","author":"Simon","year":"2008","journal-title":"BMC Infect Dis"},{"key":"R4-20261110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1086\/669082","article-title":"Distribution of pathogens in central line-associated bloodstream infections among patients with and without neutropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition.","volume":"34","author":"Steinberg","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R5-20261110","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1097\/INF.0000000000000326","article-title":"A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss Pediatric Oncology Group 2003 fever and neutropenia study.","volume":"33","author":"Agyeman","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20261110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1345\/aph.1L145","article-title":"Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections.","volume":"43","author":"Bookstaver","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R8-20261110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijantimicag.2017.06.013","article-title":"Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients.","volume":"50","author":"Norris","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20261110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jpc.14506","article-title":"Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology-oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates.","volume":"56","author":"Chong","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"R11-20261110","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/MPH.0000000000002258","article-title":"Bloodstream infections in children with cancer: pathogen distribution and antimicrobial susceptibility patterns over a 10-year period.","volume":"44","author":"Maarbjerg","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"R12-20261110","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/jcm11030880","article-title":"Characteristics and outcomes of bloodstream infections in a tertiary-care pediatric hematology-oncology unit: a 10-year study.","volume":"11","author":"Mattei","year":"2022","journal-title":"J Clin Med"},{"key":"R13-20261110","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1097\/MPH.0000000000002809","article-title":"Bloodstream infections in pediatric oncology patients: bacterial pathogen distribution and antimicrobial susceptibility at the university hospital centre Zagreb, Croatia-a 5-year analysis.","volume":"46","author":"Marekovi\u0107","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20261110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1871525721666221125093836","article-title":"A.Clinical characteristics and risk factors for bloodstream infections in children with cancer: a report from a pediatric hematology oncology unit.","volume":"21","author":"Bangeas","year":"2023","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R16-20261110","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/pbc.24482","article-title":"Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.","volume":"60","author":"Handrup","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20261110","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhin.2012.01.003","article-title":"Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.","volume":"80","author":"D\u00fcmichen","year":"2012","journal-title":"J Hosp Infect"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:01:22Z","timestamp":1794326482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005342","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}